T his article aims to set out the progress of the United Kingdom Critical Care Trials Forum (UKCCTF) to date. There have been two meetings of the forum, one at the University of Warwick on the 29th and 30th June 2009, hosted by the West Midlands Intensive Care Society with the support of both the Intensive Care National Audit and Research Centre (ICNARC) and the Intensive Care Society (ICS), and one in Edinburgh the previous year. Meetings aim to discuss the progress of clinical trials from conception and development through to delivery of results; the meetings include sessions on trial methodology from guest speakers.
The UKCCTF is currently an organisation without officers, constitution or declared mission. However, the current 'players' in the field of acute care research are represented in the forum and at their meetings. All those listed below have roles with respect to acute care research and have attended the meetings. These independent organisations provide support to different aspects of acute care research, ranging from the regional distribution of central funds (CLRN), through the coalescence of groups for the completion of specific projects, to the support of individual researchers, with only ICNARC and the CEM being involved in relatively fixed networks.
The role for the UKCCTF has been explored through a UKwide e-survey conducted before the 2009 Warwick meeting, which Mark Bellamy, Professor of Intensive Care at Leeds and Chairman of the ICS Research Committee, has summarised. The e-survey was distributed to the membership all four UK intensive care societies, the College of Emergency Medicine and both ICNARC and Contact, Help, Advice and Information Networks (CHAIN). 1 A total of 509 responses were received, approximately 89% from clinicians (3:1 consultants to trainees, see A significant minority (37.4%) of the respondents had not previously heard of the UKCCTF. Most Trusts (102/131) had recruited patients into a clinical intensive care study in the previous 18 months, although 55% did not have a research nurse and 65% did not have any dedicated research time for trainees. In contrast, ICNARC data collection clerks were available in 111/132 (84%) of Trusts. Respondents also provided information about the type of support required for research (Figure 3) , the desired format for UKCCTF meetings (Figure 4 ) and the barriers to participation in the UKCCTF (Figure 5 ).
The survey highlighted several issues. Some respondents, for example, were unsure what the UKCCTF has to offer: "I am unsure how yet more meetings will achieve an increase in productivity. Talking about doing things is not the same thing as doing things" and "conflict between ICS research group/ICS foundation and UKCCTF -do we need both?" Others were clear that the UKCCTF might have something to offer in, for example, "developing multi-professional research networks" or in helping to promote more homogeneous clinical practice: "creating a 'level playing field' of ICU behaviours for members. Until we have homogeneity, it will be hard to do good collaborative research" and "baseline standards are very variable across UK. Makes conducting multi-centre trials difficult. A system of verification/accreditation to screen potential participants would ease these concerns."
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For those hoping that the UKCCTF might replicate the Canadian Critical Care Trials Group or its antipodean equivalent, the survey revealed that there is little appetite for such an organisation among these key players. Moreover, standardisation of critical care practice would not reflect the 'real-life' situation, resulting in clinical trials with a high degree of internal validity but little or no external validity. However, there is much that the UKCCTF can offer in terms of promoting clinical research in acute care through organising meetings that provide a combination of information, education, and opportunity for networking. The survey clearly reflected a widespread concern that the UKCCTF would become dominated by people or politics: "I like the overall concept but there is a real danger that the direction becomes dominated by political agendas either locally or nationally and many developments stem from individual ideas whose potential is not necessarily realised by opinion leaders or others with vested interests."
There was also a concern that the organisation might focus on the needs of England in general, or London in particular: "too England-orientated without sufficient recognition of Scotland, Wales and Northern Ireland," and "excessively London-centric." The open structure of forum meetings mitigates against this possibility; however, the success or otherwise of the UKCCTF will absolutely depend on the continued participation of those with an interest in acute care research from all scientific disciplines, healthcare professions, types of institution, and geographic location. Failing this, participants will vote with their feet. For example, one e-survey respondent wrote: "We went to the last meeting but although it was really interesting and useful, I thought it was directionless especially considering what the Australians had achieved. I also thought it was a bit of an old boys' club and failed to recognise the contribution of all those who work in critical care research, hence we are not going to attend this year."
Ongoing clinical trials
Members of the UKCCTG are currently involved in many areas of clinical research. The following is a sample:
Kathy Rowan and the ICNARC have an impressive list of studies emerging. Risk-adjustment in neuro-critical care (RAIN) is aimed at identifying an outcome prediction model for patients with acute traumatic brain injury, in order to be able to prospectively compare outcomes and cost-effectiveness for patients managed in different types of neuro-critical care settings. It started in January 2009. IVIg is a feasibility study into the use of intravenous immunoglobulin in the treatment of severe sepsis and septic shock that started in April 2009. ICNARC have four other studies in development phase. These included fungal infection risk evaluation (FIRE), an observational study aimed at identifying risk factors in nonneutropaenic critically ill patients for the development of invasive fungal infection; OPTIMISE, an evaluation of the effect on outcome of perioperative haemodynamic optimisation in patients undergoing major gastrointestinal surgery, and CALORIES, a pragmatic, open, multicentre, randomised controlled trial (RCT) comparing early parenteral with early enteral nutrition on 30-day mortality and cost-effectiveness.
Duncan Young and his collaborators continue to recruit into the OSCAR trial, 2 a multicentre RCT of high-frequency oscillatory ventilation compared to conventional mechanical ventilation in the management of ARDS.
Gavin Perkins is leading two studies, one in progress and one yet to start. BALTI-prevention, an RCT of inhaled beta-2 adrenergic agonists for the prevention of lung injury in patients undergoing oesophagectomy, started to recruit patients in March 2008 and is progressing well. 3 PARAMEDIC is a Health Technology Assessment programme (HTA)-funded cluster RCT, examining the clinical-and cost-effectiveness of the LUCAS-2 mechanical chest compression device for Professor Fang Gao is leading the MRC-funded BALTI-2 trial, 4 a multicentre RCT of the effect of intravenous salbutamol on 28-day mortality in patients with ARDS. The trial started recruitment in December 2008 and aims to recruit 1,334 ventilated patients by the end of 2011. Recruitment has been slower than anticipated, and Professor Gao has appealed for help from the UK critical care community through the UKCCTF.
One aim of the UKCCTF is to encompass all acute care research, and therefore it encourages a strong representation from emergency medicine. Professor Steve Goodacre is the principle investigator (PI) for the 3Mg study and Tim Coats for the CRASH-2 trial. The 3Mg study 5 is an RCT comparing standard therapy plus magnesium sulphate (intravenous or nebulised) versus standard therapy alone in 1,200 patients with acute severe asthma. End-points include the proportion of patients who require admission at initial presentation or during the following week, and breathlessness. The CRASH-2 study 6 is a large, multinational RCT of antifibrinolytic therapy in trauma patients with or at risk of significant haemorrhage, examining both death and transfusion requirement. The study has been recruiting since early 2005 and is due to finish recruiting the target of 18,000 patients by the end of 2009.
Trials under development -work in progress
There are several trials in progress that the Forum supports and reports progress on.
The RELIEVE (REstrictive and LIberal transfusion strategies in intEnsiVE care) is led by its chief investigator, Professor Tim Walsh. This RCT will compare a restrictive (trigger for transfusion, haemoglobin ≤70 g/L, target 70-90 g/L) versus a liberal (trigger haemoglobin ≤90 g/L, target 90-110 g/L) transfusion threshold for patients aged over 55 years who require four or more days of mechanical ventilation. The trial is funded as a feasibility study in six UK ICUs aiming to recruit approximately 100 patients before proceeding to full grant application. Primary outcome measures relate to feasibility at this stage (compliance, transfusion exposure, difference in haemoglobin concentration) but include a range of important patient-centred outcomes that will be used to power the full trial. These include mortality at up to six months, quality of life, ventilation time, hospital and ICU length of stay, and potentially relevant adverse events including myocardial infarction, thrombotic events, and infections.
Dr Danny McCauley' s group and others have previously generated evidence suggesting that simvastatin may be of therapeutic value for the treatment of ALI/ARDS. On that basis, he has argued that a large, well-designed phase 2 clinical trial is now required to determine the effectiveness and safety of simvastatin in ALI/ARDS. Planning continues, and the outcome of funding applications are awaited.
At the inaugural meeting of the Forum in Edinburgh, Dr Anthony Gordon presented a convincing argument for a trial looking into vasopressin as early therapy in septic shock.
Although his proposal was successful at the December 2008 ICS meeting, having been selected for seed funding in the research priority setting exercise, his application for major funding from the HTA has been turned down. He is now focusing on the mechanism of the effect rather than pursuing a pure outcome study, planning to investigate a possible interaction between vasopressin and corticosteroids. He is currently in the process of planning a smaller multi-centre trial examining the effect of vasopressin on renal function.
Professor Steve Goodacre planned the MAFIA study, which was an outline proposal for a RCT comparing (a) magnesium sulphate to placebo for first line treatment of acute atrial fibrillation and (b) amiodarone to flecainide for second line treatment. He also has applied for HTA funding but has been turned down. On the other hand, the HITS-NS study, a proposal for a pilot cluster RCT comparing a policy of (a) transporting patients with serious head injury to the nearest hospital to (b) that of bypassing the nearest hospital in favour of transport to a neurosurgical centre, is being considered for funding by the HTA clinical trials funding stream.
Finally, Dr Jonathan Thompson has previously presented a draft protocol for a multicentre RCT of the use of ubiquinone in comatose patients admitted to ICU after cardiac arrest. A number of pertinent suggestions from the audience at the Forum meeting had been incorporated into the protocol and a grant application had then been submitted to the HTA in March 2009. The HTA suggested that it fell under the remit of the Efficacy and Mechanism Evaluation (EME) programme, as there were several mechanistic aspects to the study, and therefore the trial group were planning to submit an application to the EME.
What happened to that good idea?
Every good piece of research starts from an idea, but the development of an embryonic research idea from conception to the delivery of a fully-fledged clinical trial is long and arduous -many ideas fall along the wayside. Seven such research 'concepts' were presented at the first meeting of the Forum; of these, three were updated at the spring meeting. Stephen Brett, Senior Lecturer at the Hammersmith, spoke about 'Outcomes and Economics after ICU,' an observational study of patient outcomes and resource utilisation following discharge from intensive care. Since the Edinburgh meeting, the project had progressed from concept to active recruitment, which although acceptable, had been slower than anticipated. In response to this, the recruitment window for each contributing centre had been extended from three to six months. The fact that the project was up and running was evidence that studies in which enrolment is based on goodwill alone are possible; in this case it was proving difficult to recruit a high percentage of the eligible patients. There are delays in getting enthusiastic centres over the start line, with the performance of Trust Research and Development offices highly variable.
George Ntoumenopoulos, a research physiotherapist at Guys and St.Thomas', had spoken in Edinburgh on behalf of his team (Kim Perry, Andrew Jones and Shane Tibby) about a prospective observational survey looking at the impact of chest physiotherapy on ventilation, oxygenation and secretion Reports removal during high-frequency oscillatory ventilation (HFOV). However, the team realised they would need the measurement of more arterial blood gases than required for standard care and so would require submission to the Local Research Ethics Committee (LREC). Given the work required to do this, the team now plan to perform a 20-patient prospective, randomised cross-over trial.
New proposals for UK clinical trials in acute care
At the two meetings of the UKCCTF, new proposals for research have been presented and assessed for their suitability for funding. The proposals section of the forum meeting entails a formal, systematic presentation of research proposals based on the Medical Research Council' s grant application template. At the spring meeting in Warwick, presentation of proposals differed in format from the Edinburgh meeting in two important respects. First, there was a 'jury' of four clinical trials experts who each had up to three minutes to give an unprepared 'verdict.' Second, the audience used an electronic voting system to vote on two aspects of the proposed study: 'As a clinician would I want to participate in this study?' and 'As a funder, would I want to support this study?' Each speaker was given 10 minutes for the presentation, followed by 20 minutes discussion. Six speakers ( Table 1) presented their proposals to the 'dragon' s den' of jury and audience and braved the receipt of the former' s verdict and the latter' s vote. In contrast to the ambivalence towards audience voting in the e-survey, feedback from the Warwick meeting showed that 94% of the delegates liked the voting system and 79% had enjoyed the jury. Comments included "[I enjoyed] hearing differing ideas and opinions from experienced researchers regarding each proposal" and "[I enjoyed] new ideas [and] voting on new ideas." The speakers gained an invaluable insight into an outsider' s perspective of their proposals and this will have given them the opportunity to refashion their protocols in the light of the comments received. Whether this translates into more successful grant applications remains to be seen.
The next meeting of the UK Critical Care Trials Forum will be held at the Royal London Hospital; those interested should contact Dr Rupert Pearse who will co-ordinate the programme.
